Dr. Toshifumi Yokota, a Professor of Medical Genetics at the University of Alberta, is globally recognized for pioneering advancements in the treatment of muscular dystrophy. The trailblazing work on the development of the ground-breaking antisense oligonucleotide-mediated therapy for Duchenne muscular dystrophy resulted in the FDA-approved drug viltolarsen. As a scholarly contributor to over 100 peer-reviewed articles, an editor of three influential books, and a valued board member for numerous journals and organizations, Dr. Yokota’s relentless dedication to the medical field continues to revolutionize therapies for muscular dystrophy and rare diseases.